Overview

Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaA Randomized, Non-comparative Phase 2 Study

Status:
NOT_YET_RECRUITING

Trial end date:
2030-06-30

Target enrollment:

Participant gender:

Summary

This is a randomized, non-comparative, open-label, two-arm phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab plus induction chemotherapy versus adebrelimab plus SHR-8086 in patients with dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

XELOX